APAlly Perlina

Ally Perlina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ally Perlina has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Molecular therapy matching score correlates with clinical outcomes: a system for navigating cancer complexity

    by Ally Perlina, Subha Krishnan, Kevin T. Bush, Eden Romm, Jason K. Sicklick, Shumei Kato, Razelle Kurzrock

    Historically, precision medicine implies matching one biomarker to cognate monotherapies. However, next-generation precision oncology must address cancer complexity. Indeed, advanced tumors have a median of five genomic alterations; with ~700 cancer-causing genes, there are >1 trillion patterns. We describe an algorithmic Matching Score (expert-curated knowledge base within a digital reasoning framework) that evaluates cancer drugs’/drug combinations’ ability to address a patients’ entire next-generation sequencing/multi-omic-derived molecular profile. Using prospective, peer-reviewed published clinical trial and other study results analyzed retrospectively, Matching Scores were produced for 540 advanced/metastatic cancer patients (number of unique pathogenic alterations = 374); the most common cancers were breast ( n = 98) and colorectal ( n = 64). Matching Score results was evaluated with Kaplan–Meier, Univariate and Multivariate Cox regression analyses demonstrating that Matching Scores correlated significantly with improved progression-free survival (0% vs. 67–100% matching: 3.0 vs. 9.0 months, hazard ratio (HR): 0.34, P < 0.01), overall survival (0% vs. 67–100% matching: 9.0 vs. 18.7 months, HR: 0.54, P < 0.01), and clinical benefit rate (stable disease≥6 months/objective response) (0% vs. 67–100% matching: 22.1% vs. 55.9%, odds ratio: 4.59, P < 0.01). This study underscores the clinical importance of the precision medicine approach that maximizes matching of multiple molecular alterations with cognate drugs.

  • Open Access

    A Clinically Validated Human Capillary Blood Transcriptome Test For Global Systems Biology Studies

    by Ryan Toma, Nathan Duval, Benjamin Pelle, Matthew M Parks, Vishakh Gopu, Pedro J Torres, Francine R Camacho, Nan Shen, Subha Krishnan, Andrew Hatch, et al.

    To prevent and treat chronic diseases, including cancer, a global application of systems biology is needed. We report here a whole blood transcriptome test that needs only 50 μl of capillary (finge... METHOD SUMMARY This report describes an important improvement to whole blood transcriptome analysis. While current methods are complicated and expensive, the method reported here includes at-home s...


  • Open Access

    Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors

    by Alexey Dubovenko, Tatiana Serebryiskaya, Yuri Nikolsky, Tatiana Nikolskaya, Ally Perlina, Lellean JeBailey, Svetlana Bureeva, Shilpa Katta, Shiv Srivastava, Albert Dobi, et al.

    Background: Despite a growing number of studies evaluating cancer of prostate (CaP) specific gene alterations, oncogenic activation of the ETS Related Gene (ERG) by gene fusions remains the most validated cancer gene alteration in CaP. Prevalent gene fusions have been described between the ERG gene and promoter upstream sequences of androgen-inducible genes, predominantly TMPRSS2 (transmembrane protease serine 2). Despite the extensive evaluations of ERG genomic rearrangements, fusion transcripts and the ERG oncoprotein, the prognostic value of ERG remains to be better understood. Using gene expression dataset from matched prostate tumor and normal epithelial cells from an 80 GeneChip experiment examining 40 tumors and their matching normal pairs in 40 patients with known ERG status, we conducted a cancer signaling-focused functional analysis of prostatic carcinoma representing moderate and aggressive cancers stratified by ERG expression.